Compare Keysight Technologies Inc (KEYS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Medpace Holdings Inc — how do they compare? Keysight Technologies Inc trades at $381.74 (market cap $63.79B), while Medpace Holdings Inc trades at $616.43 (market cap $16.82B). The key difference: Keysight Technologies Inc is far larger — about 3.8× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,435,384). Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Medpace Holdings Inc for 14 Days on average.
| KEYS | MEDP | |
|---|---|---|
Market Cap | $63.79B | $16.82B |
Volume | 1,435,384 | 223,093 |
Sector | Technology | Health |
52-Week High | $387.90 | $630.19 |
52-Week Low | $159.49 | $393.42 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | $63.93B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.75, up 0.33% with strong technical momentum as it approaches resistance at $385. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.07 versus $2.48, supported by 19.14% net margins and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, with orders surging 56% in Q3 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and $416.63 consensus target, though elevated P/E of 50.7 presents valuation risk. Growth catalysts include AI data-center expansion and 6G wireless development, while risks involve supply constraints and competitive pressures in the testing equipment market.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
